Morgan Stanley Has Lowered Expectations for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) had its price objective decreased by equities research analysts at Morgan Stanley from $755.00 to $754.00 in a report issued on Thursday,Benzinga reports. The firm presently has an "overweight" rating on the biopharmaceutical company's stock. Morgan Stanley's price objective would indicate a potential upside of 34.26% from the stock's previous close.

Other equities analysts also recently issued research reports about the company. Wells Fargo & Company downgraded Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and decreased their price objective for the stock from $700.00 to $580.00 in a report on Friday, May 30th. The Goldman Sachs Group decreased their target price on Regeneron Pharmaceuticals from $917.00 to $804.00 and set a "buy" rating for the company in a research report on Wednesday, April 30th. Royal Bank Of Canada lowered shares of Regeneron Pharmaceuticals from a "moderate buy" rating to a "hold" rating and set a $662.00 price target for the company. in a research report on Friday, May 30th. Citigroup dropped their price target on Regeneron Pharmaceuticals from $700.00 to $650.00 and set a "buy" rating for the company in a research note on Monday, June 2nd. Finally, Argus downgraded Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Monday, June 30th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating, sixteen have issued a buy rating and three have given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $822.54.

Regeneron Pharmaceuticals Stock Performance

Shares of REGN stock traded up $9.00 on Thursday, hitting $561.58. 388,905 shares of the stock were exchanged, compared to its average volume of 1,136,208. The company has a current ratio of 4.93, a quick ratio of 4.03 and a debt-to-equity ratio of 0.09. The firm has a market capitalization of $60.63 billion, a PE ratio of 14.30, a P/E/G ratio of 2.02 and a beta of 0.33. Regeneron Pharmaceuticals has a one year low of $476.49 and a one year high of $1,211.20. The firm's 50 day moving average is $546.58 and its two-hundred day moving average is $622.59.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 29th. The biopharmaceutical company reported $8.22 earnings per share for the quarter, missing the consensus estimate of $8.83 by ($0.61). Regeneron Pharmaceuticals had a net margin of 31.94% and a return on equity of 15.27%. The business had revenue of $3.03 billion during the quarter, compared to analysts' expectations of $3.40 billion. During the same period in the previous year, the business earned $9.55 EPS. The business's revenue was down 3.7% on a year-over-year basis. Sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current fiscal year.

Institutional Trading of Regeneron Pharmaceuticals

A number of large investors have recently made changes to their positions in REGN. Brighton Jones LLC boosted its stake in shares of Regeneron Pharmaceuticals by 261.8% during the fourth quarter. Brighton Jones LLC now owns 948 shares of the biopharmaceutical company's stock valued at $675,000 after acquiring an additional 686 shares during the last quarter. Proficio Capital Partners LLC lifted its position in Regeneron Pharmaceuticals by 30.5% during the fourth quarter. Proficio Capital Partners LLC now owns 308 shares of the biopharmaceutical company's stock worth $219,000 after buying an additional 72 shares during the period. Larson Financial Group LLC lifted its position in Regeneron Pharmaceuticals by 62.0% during the fourth quarter. Larson Financial Group LLC now owns 81 shares of the biopharmaceutical company's stock worth $58,000 after buying an additional 31 shares during the period. American Assets Inc. purchased a new position in Regeneron Pharmaceuticals during the fourth quarter worth about $427,000. Finally, Johnson Investment Counsel Inc. lifted its position in Regeneron Pharmaceuticals by 73.9% during the fourth quarter. Johnson Investment Counsel Inc. now owns 487 shares of the biopharmaceutical company's stock worth $347,000 after buying an additional 207 shares during the period. Institutional investors and hedge funds own 83.31% of the company's stock.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.